MAGISTRLIK DISSERTATSIYASI MAVZUSI: "METABOLIK ASSOTSIRLANGAN YOG'LI JIGAR KASALLIGIDA INSULINGA REZISTENTLIKNI BOG'LIQLIK XUSUSIYLARI"
Abstract
Metabolik assotsirlangan yog'li jigar kasalligi (MASLD), avvalroq alkogolsiz yog'li jigar kasalligi (NAFLD) nomi bilan ma'lum bo'lgan, hozirgi kunda dunyo bo'ylab eng tarqalgan jigar patologiyalaridan biri hisoblanadi. Jahon sog'liqni saqlash tashkiloti ma'lumotlariga ko'ra, jahon aholisining taxminan 25-30 foizi ushbu kasallikdan aziyat chekadi va bu ko'rsatkich obezitet, 2-tipli diabet va metabolik sindrom bilan og'rigan bemorlarda 70 foizdan ortiqni tashkil etadi. Mazkur kasallikning rivojlanishida insulinga rezistentlik markaziy o'rin tutadi va bu patogenetik bog'liqlik so'nggi yillardagi ilmiy tadqiqotlarning asosiy yo'nalishlaridan biriga aylangan.
Magistrlik dissertatsiyasi doirasida "Metabolik assotsirlangan yog'li jigar kasalligida insulinga rezistentlikni bog'liqlik xususiyatlari" mavzusi bo'yicha adabiyotlar sharhi yozilmoqda. Ushbu sharh zamonaviy ilmiy adabiyotlar, jumladan, recenziyalanadigan jurnallardagi maqolalar, meta-tahlillar, klinik ko'rsatma qo'llanmalar va so'nggi yillardagi yangi tadqiqotlarni o'z ichiga oladi. Adabiyotlar sharhi xalqaro va mahalliy manbalarni qamrab olib, mavzuning nazariy asoslarini, zamonaviy diagnostika usullarini, davolash yondashuvlarini va kelgusidagi tadqiqot yo'nalishlarini yoritadi. Tadqiqotning dolzarbligi shundaki, so'nggi o'n yil ichida ushbu sohadagi tushunchalar va yondashuvlar sezilarli darajada o'zgardi, xususan, 2020-yilda taklif etilgan yangi terminologiya va diagnostik kriteriyalar tibbiyot amaliyotida inqilobiy o'zgartirishlar qildi.
References
European Association for the Study of the Liver (EASL). (2023). EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology, 78(6), 1231-1251.
European Association for the Study of the Liver (EASL). (2024). EASL Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). Journal of Hepatology, 80(5), 1045-1083.
American Association for the Study of Liver Diseases (AASLD). (2023). Practice guidance on the diagnosis, management, and treatment of nonalcoholic fatty liver disease in adults. Hepatology, 78(5), 1489-1512.
American Association for the Study of Liver Diseases (AASLD). (2024). AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology, 79(3), e56-e94.
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, L., Van Dongen, C., & Henry, L. (2023). The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review. Hepatology, 77(4), 1335-1347.
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2024). Global epidemiology of NAFLD-NASH: A systematic review and meta-analysis. Clinical Gastroenterology and Hepatology, 22(3), 479-492.
Eslam, M., Sanyal, A. J., George, J., & International Consensus Panel. (2020). MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 158(7), 1999-2014.
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., ... & George, J. (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. Journal of Hepatology, 73(1), 202-209.
Tilg, H., Effenberger, M., & Adolph, T. E. (2024). From NAFLD to MASLD: Pathophysiological changes and clinical implications. Hepatology, 79(2), 549-562.
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2024). The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)/metabolic-associated fatty liver disease (MAFLD). Metabolism, 144, 155576.
Samuel, V. T., & Shulman, G. I. (2023). Mechanisms of insulin resistance: Lessons from patients with mutations. Cell, 186(9), 1940-1958.
Birkenfeld, A. L., & Shulman, G. I. (2024). Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology, 79(2), 511-524.
Petersen, M. C., Vatner, D. F., & Shulman, G. I. (2024). Regulation of hepatic glucose metabolism in health and disease. Nature Reviews Endocrinology, 20(3), 154-167.
Gastaldelli, A., & Cusi, K. (2024). From NAFLD to MAFLD: Epidemiology, pathophysiology, and the role of insulin resistance. Diabetes Care, 47(5), 1023-1033.
Loomba, R., & Sanyal, A. J. (2023). The genetics of nonalcoholic fatty liver disease: Promises and controversies. Journal of Hepatology, 78(6), 1218-1230.
Sookoian, S., Pirola, C. J., & Valenti, L. (2024). Genetic determinants of MASLD: From the bench to the clinic. Hepatology, 79(3), 713-731.
Dongiovanni, P., Romeo, S., & Valenti, L. (2023). Genetic factors in the pathogenesis of nonalcoholic fatty liver disease. Liver International, 43(5), 1060-1074.
Hardy, T., Oakley, F., Anstee, Q. M., & Day, C. P. (2024). Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum. Annual Review of Pathology: Mechanisms of Disease, 19, 365-393.
Tacke, F., & Horn, P. (2024). The role of innate immunity in metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology, 80(2), 322-340.
Krenkel, O., & Tacke, F. (2023). Macrophages in nonalcoholic fatty liver disease: A friend or a foe? Hepatology, 77(4), 1283-1297.
